HOUSE No. 3242

The Commonwealth of Massachusetts

PRESENTED BY:

Kate Hogan

To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General Court assembled:

The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying bill:

An Act to review the quality and patient safety of dispensing certain cancer and chronic disease related drugs.

PETITION OF:

NAME:	DISTRICT/ADDRESS:	DATE ADDED:
Kate Hogan	3rd Middlesex	1/20/2017
Chris Walsh	6th Middlesex	1/20/2017
Steven Ultrino	33rd Middlesex	2/3/2017
Thomas M. Stanley	9th Middlesex	2/3/2017
Jennifer E. Benson	37th Middlesex	
Smitty Pignatelli	4th Berkshire	
Jason M. Lewis	Fifth Middlesex	
Bradford R. Hill	4th Essex	
Colleen M. Garry	36th Middlesex	
Keiko M. Orrall	12th Bristol	
Jennifer L. Flanagan	Worcester and Middlesex	
Sean Garballey	23rd Middlesex	
Danielle W. Gregoire	4th Middlesex	
Bruce E. Tarr	First Essex and Middlesex	
Daniel M. Donahue	16th Worcester	
Mary S. Keefe	15th Worcester	
James J. O'Day	14th Worcester	

HOUSE No. 3242

By Ms. Hogan of Stow, a petition (accompanied by bill, House, No. 3242) of Kate Hogan and others for legislation to analyze health insurance payer practices that require certain categories of drugs. Public Health.

The Commonwealth of Alassachusetts

In the One Hundred and Ninetieth General Court (2017-2018)

An Act to review the quality and patient safety of dispensing certain cancer and chronic disease related drugs.

Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority of the same, as follows:

- 1 SECTION 1. The health policy commission, in consultation with the department of
- 2 public health and the division of insurance, shall study and analyze health insurance payer
- 3 practices that require certain categories of drugs, including those that are administered by
- 4 injection or infusion, to be dispensed by a third-party specialty pharmacy directly to a patient or
- 5 to a health care provider with the designation that such drugs be used for a specific patient and
- 6 not for the general use of the provider. The commission shall file a report of its findings,
- 7 including recommended legislation, with the senate and house committees on ways and means,
- 8 the joint committee on health care financing and the joint committee on public health not later
- 9 than January 1, 2018.